A Phase 2/3 Open-label, Randomized, Sequential Dose Escalation Cohort Study of T2307 Versus Standard of Care in Treatment of Subjects with Candidemia due to Candida Auris and other Drug-resistant Candida Species: An Adaptive Design Study


Total Award Amount

  • 222750.00
  • Direct Costs

  • 151143.00
  • Sponsor Award Id

  • R34AI150517
  • Contributor

  • Gerald McGwin   Investigator  
  • Peter Pappas M.D.   Principal Investigator  
  • Todd McCarty   Investigator